From a Small Garage to Big Success: The Story of Arc Specialties

 

From its inception in 1983 to now, ARC Specialties has become a case study in the growth of an American entrepreneurial endeavor. Company President Dan Allford took the business out of a garage and has since turned the automated manufacturing systems provider into an international enterprise.

On the first episode of The Roboticist Chronicles, host Tyler Kern sat down with Allford to explore the history of ARC Specialties and analyze how its trials and tribulations reflect growth and challenges within the industry.

Continuity and steady growth kept ARC on an upward trajectory over the decades, and Allford said that sometimes it is not about what a company does, but what it does not do.

“As long as you keep your mistakes commensurate with the size of your business, you’ll survive. So, while we were small, we made small mistakes, and we survived,” Allford said.

ARC has endured the globalization of manufacturing which has seen jobs leave the United States, but Allford said the industry is entering a renaissance in America today. Certainly, that is a welcome sight to Allford, who after almost forty years still has an unwavering passion for welding and manufacturing.

“I still like building things,” he said. “The only thing better than building something is building something that builds something.”

After creating jobs in more than 20 countries, Allford’s greatest build may not be a product but an exemplary company.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More